Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib Phase 3 Study (Japan)
jRCT2080225189Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
01
Overview
Phase 3 trial of baricitinib, sponsored by Eli Lilly and Company. Started May 2020; status: completed.
02
Drugs
baricitinib
Beyond the preview
Go deeper on jRCT2080225189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225189.